Irinotecan 40mg
| Product Overview | |
| Generic Name | Irinotecan 40mg |
| Brand Name(s) | Campto® (Pfizer), Irinotel® |
| Form | Inj Vial |
| Strength | 40 mg /2 mL |
| Therapeutic Class | Topoisomerase I inhibitor |
| ATC Code | L01XX19 |
| Manufacturing & Regulatory | |
| Manufacturer | Multiple Firms |
| Country | Canada, USA, India |
| GMP Compliance | WHO-GMP certified facility |
| DMF/CEP | Unknown – request from mfg |
| COFEPRIS | Registered – exact Clave pending |
| Free Sale Certificate | Yes, available as COPP/CPP |
| Logistics & Export | |
| MOQ | 10 vials |
| Shelf Life | 12-24 Months |
| Storage | 2–8 °C, cool & dry |
| Incoterms | Exworks, DDP, FOB |
| Lead Time | 2 weeks |
| Documentation | |
| Certificate of Analysis (COA) | Manufacturer provides COA |
| SDS | Available on request |
| CTD Summary | CTD proprietary; available under commercial agreement/license |
Description
Indications & Usage: Antineoplastic agent in FOLFIRI regimens for metastatic colorectal cancer; causes diarrhea and neutropenia; blocks topoisomerase I preventing DNA replication. Used in FOLFIRI, second-line colorectal, other GI tumors; diarrhoea and myelosuppression risk.
